News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
357,728 Results
Type
Article (25535)
Company Profile (158)
Press Release (332035)
Multimedia
Podcasts (42)
Webinars (5)
Section
Business (94069)
Career Advice (819)
Deals (17717)
Drug Delivery (97)
Drug Development (47829)
Employer Resources (62)
FDA (10467)
Job Trends (8490)
News (174641)
Policy (20946)
Tag
2024 BioCapital Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (1)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (5)
2025 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (1894)
Academic (1)
Accelerated approval (4)
Adcomms (23)
Allergies (62)
Alliances (26158)
ALS (68)
Alzheimer's disease (812)
Antibody-drug conjugate (ADC) (73)
Approvals (10479)
Artificial intelligence (168)
Autoimmune disease (11)
Automation (9)
Bankruptcy (117)
Best Places to Work (7755)
BIOSECURE Act (15)
Biosimilars (85)
Biotechnology (119)
Bladder cancer (62)
Brain cancer (17)
Breast cancer (177)
Cancer (1510)
Cardiovascular disease (135)
Career advice (699)
Career pathing (14)
CAR-T (95)
Cell therapy (302)
Cervical cancer (13)
Clinical research (39491)
Collaboration (573)
Compensation (226)
Complete response letters (23)
COVID-19 (1702)
CRISPR (38)
C-suite (168)
Cystic fibrosis (74)
Data (1587)
Decentralized trials (1)
Denatured (15)
Depression (26)
Diabetes (200)
Diagnostics (3447)
Digital health (13)
Diversity (7)
Diversity, equity & inclusion (15)
Drug discovery (84)
Drug pricing (80)
Drug shortages (26)
Duchenne muscular dystrophy (70)
Earnings (33246)
Editorial (30)
Employer branding (6)
Employer resources (56)
Events (51175)
Executive appointments (445)
FDA (11350)
Featured Employer (33)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (7)
Funding (441)
Gene editing (89)
Generative AI (17)
Gene therapy (255)
GLP-1 (519)
Government (3549)
Grass and pollen (5)
Guidances (37)
Healthcare (11180)
Huntington's disease (18)
IgA nephropathy (24)
Immunology and inflammation (66)
Indications (26)
Infectious disease (1805)
Inflammatory bowel disease (113)
Inflation Reduction Act (4)
Influenza (34)
Intellectual property (52)
Interviews (139)
IPO (9672)
IRA (26)
Job creations (1206)
Job search strategy (608)
Kidney cancer (8)
Labor market (11)
Layoffs (230)
Leadership (7)
Legal (3714)
Liver cancer (45)
Lung cancer (245)
Lymphoma (124)
Machine learning (3)
Management (21)
Manufacturing (218)
MASH (49)
Medical device (5875)
Medtech (5878)
Mergers & acquisitions (8430)
Metabolic disorders (514)
Multiple sclerosis (59)
NASH (20)
Neurodegenerative disease (54)
Neuropsychiatric disorders (12)
Neuroscience (1196)
NextGen: Class of 2025 (3284)
Non-profit (2362)
Northern California (1536)
Now hiring (8)
Obesity (289)
Opinion (125)
Ovarian cancer (47)
Pain (59)
Pancreatic cancer (39)
Parkinson's disease (99)
Partnered (13)
Patents (145)
Patient recruitment (68)
Peanut (34)
People (30088)
Pharmaceutical (39)
Pharmacy benefit managers (11)
Phase I (11195)
Phase II (16559)
Phase III (14788)
Pipeline (776)
Policy (109)
Postmarket research (1777)
Preclinical (4457)
Press Release (21)
Prostate cancer (82)
Psychedelics (21)
Radiopharmaceuticals (185)
Rare diseases (275)
Real estate (2659)
Recruiting (23)
Regulatory (15321)
Reports (21)
Research institute (1638)
Resumes & cover letters (120)
Rett syndrome (4)
RNA editing (3)
RSV (33)
Schizophrenia (54)
Series A (77)
Series B (56)
Service/supplier (2)
Sickle cell disease (44)
Southern California (1264)
Special edition (6)
Spinal muscular atrophy (103)
Sponsored (15)
Startups (1807)
Stomach cancer (11)
Supply chain (48)
Tariffs (35)
The Weekly (26)
United States (13249)
Vaccines (490)
Venture capitalists (25)
Weight loss (194)
Women's health (22)
Worklife (4)
Date
Today (92)
Last 7 days (537)
Last 30 days (1626)
Last 365 days (20410)
2025 (6563)
2024 (21746)
2023 (24208)
2022 (31904)
2021 (34684)
2020 (32647)
2019 (27273)
2018 (20079)
2017 (18584)
2016 (16928)
2015 (19274)
2014 (14120)
2013 (11973)
2012 (12727)
2011 (13040)
2010 (10438)
Location
Africa (429)
Alabama (28)
Alaska (2)
Arizona (72)
Arkansas (4)
Asia (23736)
Australia (3483)
California (3368)
Canada (1125)
China (356)
Colorado (124)
Connecticut (162)
Delaware (109)
Europe (60150)
Florida (486)
Georgia (109)
Idaho (27)
Illinois (310)
India (20)
Indiana (199)
Iowa (6)
Japan (129)
Kansas (54)
Kentucky (9)
Louisiana (9)
Maine (28)
Maryland (567)
Massachusetts (2713)
Michigan (73)
Minnesota (151)
Mississippi (1)
Missouri (46)
Montana (13)
Nebraska (11)
Nevada (22)
New Hampshire (20)
New Jersey (1228)
New Mexico (14)
New York (1064)
North Carolina (585)
North Dakota (5)
Northern California (1536)
Ohio (130)
Oklahoma (5)
Oregon (24)
Pennsylvania (748)
Puerto Rico (4)
Rhode Island (19)
South America (566)
South Carolina (10)
Southern California (1264)
Tennessee (38)
Texas (455)
Utah (110)
Virginia (95)
Washington D.C. (38)
Washington State (341)
West Virginia (1)
Wisconsin (35)
357,728 Results for "european medicines agency ema".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)
April 2, 2025
·
2 min read
Press Releases
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
April 24, 2025
·
8 min read
Press Releases
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
April 28, 2025
·
4 min read
Press Releases
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
March 31, 2025
·
6 min read
Press Releases
Comanche Biopharma Announces European Medicines Agency (EMA) Has Granted Orphan Drug Designation for CBP-4888 in sFlt1-mediated Preterm Preeclampsia
April 8, 2025
·
4 min read
Press Releases
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
March 28, 2025
·
7 min read
Genetown
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the European Medicines Agency (EMA) has reset the review of the marketing authorization application (MAA) for intravitreal pegcetacoplan for geographic atrophy to the last phase of the initial assessment (day 180).
April 26, 2024
·
2 min read
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
Edgewise Therapeutics, Inc. today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designations for sevasemten for the treatment of Becker muscular dystrophy (Becker) and for the treatment of Duchenne muscular dystrophy (Duchenne).
April 23, 2024
·
5 min read
Lone Star Bio
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin’s Treatment of Acute Myeloid Leukemia (AML)
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of AML.
April 18, 2024
·
5 min read
Press Releases
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
April 4, 2025
·
3 min read
1 of 35,773
Next
